Zdrowie i gospodarka · 13/02/2023

FDA Clears ARISTOSPAN Injectable Suspension for Approval

The FDA has determined that ARISTOSPAN (triamcinolone hexacetonide) injectable suspension, 20 mg/mL and 5 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of generic versions.